GEN-MKT-18-7897-A
Nov 18, 2015 | Blogs, Forensic | 0 comments
Facts about Synthetic Cannabinoids and why you need to pay attention to evolving science
Mass spectrometry has proven an excellent tool for testing due to its flexibility to add new analytes as soon as new references become available. Even more compounds have been added to the DEA’s list of controlled substances.
Forensic screening methods for JWH-018 and JWH-073 and their metabolites (two of the main ingredients found in synthetic cannabinoids) using QTRAP technology have already been developed. In 2010, and this validated forensic screening method has been updated to detect JWH-081 and JWH-250 and their metabolites. This is important news when it comes to drug enforcement since the DEA initially announced they would be controlling five synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47, and CP47-C8 homologue). Meanwhile, replacement compounds quickly emerged to include JWH- 081 and JWH-250.
You can read about the results in, “Detecting a New Wave of K2/Spice in Human Urine.” The main takeaways from the article are this:
Download to learn more:
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network